

## Supporting Online Material

### **Inhibitory mechanism of the Q $\beta$ lysis protein A<sub>2</sub>**

C. Reed<sup>1</sup>, C. Langlais<sup>1†</sup>, V. Kuznetsov<sup>2</sup>, and R. Young<sup>1\*</sup>

<sup>1</sup>Department of Biochemistry and Biophysics, Texas A&M University, 2128 TAMU, College Station, Texas 77843-2128

<sup>2</sup>Department of Chemistry, Texas A&M University, College Station, Texas 77843

<sup>†</sup>**Present address:** Rho, Inc., 6330 Quadrangle Drive, Chapel Hill, NC 27517

**\*Corresponding author.**

**Mailing address:** Department of Biochemistry and Biophysics, Texas A&M University, 2128 TAMU, College Station, TX 77843-2128

Phone: (979) 845-2087

Fax: (979) 862-4718

E-mail: ryland@tamu.edu

## Supplementary Methods

**Plasmid construction.** For yeast-two-hybrid analyses, plasmids pGBKT7-A<sub>2</sub> and pGADT7-murA/murA<sup>L138Q</sup> were amplified in XL-1 Blue. pGBKT7-A<sub>2</sub> was cloned from a cDNA copy of the Q $\beta$  RNA reverse transcribed using the M-MLV Reverse Transcriptase according to manufacturer's instructions (Ambion). A<sub>2</sub> was amplified by PCR using A<sub>2</sub>KpnI-NdeI-For (GTATAAGAGGTACCACATATGCCTAAATTACC) and A<sub>2</sub>Rev-BamHI (GCAGCCGGATCCAGTTTCA) primers. The PCR product was inserted into pGBKT7 (Clontech) at the BamHI and an NdeI restriction site that was introduced upstream of the *myc* epitope tag by site-directed mutagenesis, described previously (Smith et al., 1998), with the following primers: pGBKT7-NdeI-up-FOR (GGGCGAGCCGCCCATATGGAGGAGC) and pGBKT7-NdeI-up-Rev (CTGCTCCTCCATATGGGCGGCTCGCC). pGADT7-murA/murA<sup>L138Q</sup> was similarly constructed by inserting *murA/murA*<sup>L138Q</sup> amplified from pZE12-murA/murA<sup>L138Q</sup> by PCR with the primers NcoI-murA-FOR (TTGGTTCCATGGATAAATTTTCGTG) and BamHI-murA-REV (TATTATTCTAGAGGATCCGCTCTCAGACGATTAACCAC) into the NcoI and BamHI sites of pGADT7 (Clontech). Construction of pZE12-murA has been previously described (Bernhardt et al., 2001). Alleles of *murA*\* used in the MurA bioassay were constructed by site-directed mutagenesis (Smith et al., 1998) into pZE12-murA with primers listed in Supplementary Table S2. For purification, an oligo-histidine tag (G<sub>2</sub>H<sub>6</sub>G<sub>2</sub>) was adjoined to the C-terminus of *murA* by site-directed PCR mutagenesis. To generate pZA31-murA<sup>Bs</sup>, *murAA* (*murA*<sup>Bs</sup>) was cloned out of *Bacillus subtilis* W23 with the following primers: KpnI-NdeI-BsMurA-For ATATATGGTACCCATATGGAAAAAAT and XbaI-BamHI-BsMurA-Rev GAGTGGTCTAGAGGATCCTTATGCAT and ligated into pZA31 (Lutz & Bujard, 1997) at the KpnI and XbaI restriction sites. This plasmid has a P<sub>Ltet0-1</sub> promoter which is constitutively on in a *tetR* background. The MBP-A<sub>2</sub> fusion vector, pETMBP-A<sub>2</sub>, was constructed by amplifying the A<sub>2</sub> gene via PCR, as described above, using KpnI-NdeI-For GTATAAGAGGTACCACATATGCCTAAATTACC and A<sub>2</sub>Rev-BamHI GCAGCCGGATCCAGTTTCA primers. The PCR product was digested with NdeI and BamHI and ligated into p202 (pET28b-MBP vector with a TEV protease cleavage site, kindly provided by Dr. Sacchettini, TAMU) similarly digested.

***MurA purification.*** Purification of MurA bound with UDP-NAM and PEP was performed according to the purification protocol described Experimental procedures section of the main text except the ammonium sulfate precipitation steps were removed.

***Substrate analysis.*** Residual nucleotide binding of purified MurA was tested by denaturation and deproteinization of the sample according to the method previously described (Mizyed *et al.*, 2005). Absorbance of the sample at 260 nm was assessed. No residual nucleotide binding was observed for MurA purified with successive ammonium sulfate precipitation steps (data not shown).

## Supplementary Tables and Figures


**Table S1. MurA<sup>\*D305A</sup> Q $\beta$  protection assay.**

<b>Protects</b>	<b>Does not Protect</b>
<b>No plaques</b>	<b>Plaques</b>
WT (D305A)	L138Q
L111R	V87R
S127R	K88E
E130A	A119R
Q131R	P121R
G133R	V122R
T135R	I126R
K137D	E130R
L138P	I136R
E139A	L138M
E139R	L138R
E140R	V143R
G141R	I156R
K152R	N330R
H155R	F332R
V157R	M333R
D159R	P336R
K160R	M366R
V335R	T368R
R391R	H394R


**Table S2. Primers for construction of MurA\* alleles.**

Allele ( <i>murA</i> *)	Sequence
L138Q	FOR: ACCATCAAACCTGGAAGAAGGT REV: ACCTTCTTCCAGTTTGATGGT
L138M	FOR: ACCATCAAATGGAAGAAGGT REV: ACCTCCTTCCATTTTGATGGT
L138P	FOR: ACCATCAAACCGGAAGAAGGT REV: ACCTCCTTCCGGTTTGATGGT
L138R	FOR: ACCATCAAACGGGAAGAAGGT REV: ACCTTCTTGCCGTTTGATGGT
A119R	FOR: GTACGATCGGTCGTCCGGTTG REV: CAACCGGACGACGACCGATCGTAC
P121R	FOR: CGGTGCGCGTCGTGTTGATCTAC REV: GTAGATCAACACGACGCGCACCG
V122R	FOR: GTGCGCGTCCGCGTGATCTACACATT REV: AATGTGTAGATCACGCGGACGCGCAC
D123R	FOR: GCGCGTCCGGTTCGTCTACACATTTT REV: GAAATGTGTAGACGAACCGGACGCGC
I126R	FOR: GATCTACACCGTTCTGGCCTCGAAC REV: GTTCGAGGCCAGAACGGTGTAGATC
S127R	FOR: GATCTACACATTCGTGGCCTCGAAC REV: GTTCGAGGCCACGAATGTGTAGATC
E130A	FOR: TCTGGCCTCGCACAATTAGGC REV: GCCTAATTGTGCGAGGCCAGA
E130R	FOR: CTGGCCTCCGTCAATTAGGCGCG REV: CGCGCCTAATTGACGGAGGCCAG
Q131R	FOR: CTGGCCTCGAACGTTTAGGCGCGAC REV: GTCGCGCCTAACGTTTCGAGGCCAG
G133R	FOR: CCTCGAACAATTACGTGCGACCATCAA REV: TTGATGGTCGCACGTAATTGTTTCGAGG
A134R	FOR: AACAATTAGGCCGTACCATCAAAC REV: GTTTGATGGTACGGCCTAATTGTT
T135R	FOR: AATTAGGCGCGCGTATCAAACCTGGA REV: TCCAGTTTGATACGCGCGCCTAATT
I136R	FOR: TAGGCGCGACCCGTAAACTGGAAGA REV: TCTTCCAGTTTACGGGTCGCGCCTA
E139A	FOR: ATCAAACCTGGCAGAAGGTTAC REV: GTAACCTTCTGCCAGTTTGAT
E139R	FOR: GCGACCATCAAACCTGCGTGAAGGTTA REV: CGTAACCTTCACCGAGTTTGATGGTC

K137D	FOR: GCGACCATCGATCTGGAAGAAGG
	REV: CCTTCTTCCAGATCGATGGTCGC
G141R	FOR: AACTGGAAGAACGTTACGTTAAA
	REV: TTTAACGTAACGTTCTTCCAGTT
V143R	FOR: GAAGAAGGTTACCGTAAAGCTTCCG
	REV: CGGAAGCTTTACGGTAACCTTCTTC
K152R	FOR: GATGGTCGTTTGCCTGGTGCACATATC
	REV: GATATGTGCACCACGCAAACGACCATC
H155R	FOR: GAAAGGTGCACGTATCGTGATGG
	REV: CCATCACGATACGTGCACCTTTC
D159R	FOR: ATCGTGATGCGTAAAGTCAGCG
	REV: CGCTGACTTTACGCATCAC
K160E	FOR: GTGATGGATGAAGTCAGCGTT
	REV: AACGCTGACTTCATCCATCAC
D305A	FOR: GCATTCCCGACCGCTATGCAGGCC
	REV: GGCCTGCATAGCGGTCGGGAATGC
E329R	FOR: GAAACGGTCTTTCGTAACCGCTTTATGC
	REV: GCATAAAGCGGTTACGAAAGACCGTTTC
N330R	FOR: CGGTCTTTGAACGTCGCTTTATGC
	REV: GCATAAAGCGACGTTCAAAGACCG
E332R	FOR: CTTTGAAAACCGCCGTATGCATGTGCC
	REV: GGCACATGCATACGGCGGTTTTCAAAG
M333R	FOR: GAAAACCGCTTTCGTGCATGTGCCAGAG
	REV: CTCTGGCACATGACGAAAGCGGTTTTTC
V335R	FOR: CGCTTTATGCATCGTCCAGAGCTG
	REV: CAGCTCTGGACGATGCATAAAGCG
P336R	FOR: GCTTTATGCATGTGCGTGAGCTGAGCC
	REV: GGCTCAGCTCACGCACATGCATAAAGC
E337R	FOR: GCATGTGCCACGTCTGAGCCGTATGGC
	REV: GCCATACGGCTCAGACGTGGCACATGC
R340E	FOR: GAGCTGAGCGAAATGGGCGCGCACGCC
	REV: GGCGTGCGCGCCCATTTTCGCTCAGCTC
M366R	FOR: CGCACAGGTTTCGTGCAACCGATCTGCG
	REV: CGCAGATCGGTTGCACGAACCTGTGCG
T368R	FOR: GGTTATGGCACGTGATCTGCGTGC
	REV: GCACGCAGATCACGTGCCATAACC
R391E	FOR: CGGTGGTTGATGAAATTTATCACATCG
	REV: CGATGTGATAAATTTTCATCAACCACCG
H394R	FOR: GATCGTATTTATCGTATCGATCGTGGC
	REV: GCCACGATCGATACGATAAATACGATC




**Fig. S1. A<sub>2</sub> does not bind the dormant complex of MurA.** Fusion cleavage analysis of A<sub>2</sub>-MurA binding in the presence of MurA liganded to UDP-NAM (UNAM) and PEP (P). MBP-A<sub>2</sub> was cleaved with TEV protease. UDP-NAG (UNAG, 1 mM) was included in a reaction. Binding was assessed as A<sub>2</sub> solubility after centrifugation: Total fraction (T), supernatant after centrifugation (S), and pellet fraction (P). Samples were resolved on SDS-PAGE and immunoblotted with the  $\alpha$ -A<sub>2</sub> antibody. MBP-A<sub>2</sub> has an apparent MW of 100 kDa and cleaved A<sub>2</sub> ~50 kDa. UNAM/P was included in quotation marks since it was previously determined that a small fraction of MurA co-purifies with these two substrates (Mizyed *et al.*, 2005, Zhu *et al.*, 2012).




**Fig. S2. Substrate-dependent analyses of MurA catalytic loop conformations.** (A) Overlay of *E. coli* MurA bound with UDP-NAG (Han H., unpublished; PDB entry 3KQJ; blue), UDP-NAG/PEP (Skarzynski *et al.* 1998; PDB entry 1A2N; red), and UDP-NAG/fosfomicin (Skarzynski *et al.* 1996; PDB entry 1UAE; green); (B) Enlargement of structure active site/catalytic loop in part A. Distance between Gly114 residues is displayed. The catalytic loop is highlighted with an asterisk. The RMSD value of the catalytic loop region between the three structures is 1.477 Å. Figures were generated using PyMOL (Schrödinger, 2010).







**Fig. S3. A<sub>2</sub> binds MurA<sup>L138Q</sup>.** Fusion cleavage of MBP-A<sub>2</sub> was tested in the presence of UDP-NAG bound MurA and MurA<sup>L138Q</sup>. Solubility of A<sub>2</sub> after centrifugation: Total fraction (T), supernatant after centrifugation (S), and pellet fraction (P) was assessed by Western blot that was probed with the  $\alpha$ -A<sub>2</sub> antibody.




**Fig. S4. MurA protection assay induction series.** Protection from  $Q\beta$  plating is observed on induction plates of  $100 \mu\text{M}$  IPTG or greater.  $Q\beta$  phage and bacteria are included in agar overlay on plates containing increasing amounts of IPTG ( $\mu\text{M}$ ): (A) 0, (B) 12.5, (C) 25, (D) 50, (E) 100 and (F) 1000.



**Fig. S5. MurA variants are expressed.** TCA precipitated cells expressing MurA variants were run on SDS-PAGE. Alleles are shown above lanes. Uninduced control (ui) and Luciferase control (Luc)



**Fig. S6. MurA mutant surface maps.** (A) MurA mutational data. Catalytic loop displayed as grey spheres. *Rats* are colored red. Residues providing protect  $\geq$ WT are shown in purple (weaker WT induction phenotype is lighter purple). Residues that are non-functional are shown as yellow spheres. (B) Differentiation of *rat* residues. Basal level protection *rats* are displayed as red spheres. Medium protecting *rats* are colored orange. Low protecting *rats* are shown in yellow. All residues were mapped onto the MurA UDP-NAG-bound state ("closed" conformation, front view) (Han H., unpublished; PDB entry 3KQJ). Figures were generated using PyMOL (Schrödinger, 2010).



**Fig. S7. The surface of MurA has negatively charged and hydrophobic characteristic.** (Red) negatively charged residues, (blue) positively charged residues, and (white) hydrophobic residues. MurA tetrahedral intermediate (PDB entry 1A2N) (Skarzynski *et al.*, 1998) was used to generate figures with the online server: (<http://kryptonite.nbc.net/pdb2pqr/>) (Dolinsky TJ, 2004). (A) surface view (B) transparent view

## References

- Bernhardt, T. G., I. N. Wang, D. K. Struck & R. Young, (2001) A protein antibiotic in the phage Q $\beta$  virion: Diversity in lysis targets. *Science* **292**: 2326-2329.
- Dolinsky TJ, N. J., McCammon JA, Baker NA, (2004) PDB2PQR: An automated pipeline for the setup, execution, and analysis of Poisson-Boltzmann electrostatics calculations. *Nucleic Acids Res.* **32**: W665-W667.
- Lutz, R. & H. Bujard, (1997) Independent and tight regulation of transcriptional units in *Escherichia coli* via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. *Nucleic Acids Res.* **25**: 1203-1210.
- Mizyed, S., A. Oddone, B. Byczynski, D. W. Hughes & P. J. Berti, (2005) UDP-N-acetylmuramic acid (UDP-MurNAc) is a potent inhibitor of MurA (enolpyruvyl-UDP-GlcNAc synthase). *Biochemistry* **44**: 4011-4017.
- Schrödinger, LLC, (2010) The PyMOL Molecular Graphics System, Version 0.99.
- Skarzynski, T., D. H. Kim, W. Lees, C. T. Walsh & K. Duncan, (1998) Stereochemical course of enzymatic enolpyruvyl transfer and catalytic conformation of the active site revealed by the crystal structure of the fluorinated analogue of the reaction tetrahedral intermediated bound to the active site of the C115A mutant of MurA. *Biochemistry* **37**: 2572-2577.
- Smith, D. L., D. K. Struck, J. M. Scholtz & R. Young, (1998) Purification and biochemical characterization of the lambda holin. *J. Bacteriol.* **180**: 2531-2540.
- Zhu, J.-Y., Y. Yang, H. Han, S. Betzi, S. H. Olesen, F. Marsilio & E. Schönbrunn, (2012) Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). *J. Biol. Chem.* **287**: 12657-12667.